Because higher levels of CDK4 and its downstream effector E2F1 were observed in STSs (Figure 4E and Figure 6A), we speculated that inhibiting CDK4 might prolong the survival of HCC patients. Here, E2F1 is linked to hepatocellular carcinoma.